We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Assertio (ASRT) Stock Moves -0.41%: What You Should Know
Read MoreHide Full Article
In the latest trading session, Assertio (ASRT - Free Report) closed at $2.45, marking a -0.41% move from the previous day. This move was narrower than the S&P 500's daily loss of 0.74%. Elsewhere, the Dow gained 0.01%, while the tech-heavy Nasdaq added 0.05%.
Prior to today's trading, shares of the drugmaker had gained 10.31% over the past month. This has outpaced the Medical sector's gain of 4.57% and the S&P 500's gain of 4.58% in that time.
Wall Street will be looking for positivity from Assertio as it approaches its next earnings report date. On that day, Assertio is projected to report earnings of $0.07 per share, which would represent a year-over-year decline of 12.5%. Our most recent consensus estimate is calling for quarterly revenue of $31.33 million, up 23.01% from the year-ago period.
ASRT's full-year Zacks Consensus Estimates are calling for earnings of $0.51 per share and revenue of $135.86 million. These results would represent year-over-year changes of +1800% and +22.38%, respectively.
Investors should also note any recent changes to analyst estimates for Assertio. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Assertio currently has a Zacks Rank of #3 (Hold).
In terms of valuation, Assertio is currently trading at a Forward P/E ratio of 4.79. Its industry sports an average Forward P/E of 14.45, so we one might conclude that Assertio is trading at a discount comparatively.
Investors should also note that ASRT has a PEG ratio of 0.48 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Medical - Drugs stocks are, on average, holding a PEG ratio of 1.39 based on yesterday's closing prices.
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 81, which puts it in the top 33% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Assertio (ASRT) Stock Moves -0.41%: What You Should Know
In the latest trading session, Assertio (ASRT - Free Report) closed at $2.45, marking a -0.41% move from the previous day. This move was narrower than the S&P 500's daily loss of 0.74%. Elsewhere, the Dow gained 0.01%, while the tech-heavy Nasdaq added 0.05%.
Prior to today's trading, shares of the drugmaker had gained 10.31% over the past month. This has outpaced the Medical sector's gain of 4.57% and the S&P 500's gain of 4.58% in that time.
Wall Street will be looking for positivity from Assertio as it approaches its next earnings report date. On that day, Assertio is projected to report earnings of $0.07 per share, which would represent a year-over-year decline of 12.5%. Our most recent consensus estimate is calling for quarterly revenue of $31.33 million, up 23.01% from the year-ago period.
ASRT's full-year Zacks Consensus Estimates are calling for earnings of $0.51 per share and revenue of $135.86 million. These results would represent year-over-year changes of +1800% and +22.38%, respectively.
Investors should also note any recent changes to analyst estimates for Assertio. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Assertio currently has a Zacks Rank of #3 (Hold).
In terms of valuation, Assertio is currently trading at a Forward P/E ratio of 4.79. Its industry sports an average Forward P/E of 14.45, so we one might conclude that Assertio is trading at a discount comparatively.
Investors should also note that ASRT has a PEG ratio of 0.48 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Medical - Drugs stocks are, on average, holding a PEG ratio of 1.39 based on yesterday's closing prices.
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 81, which puts it in the top 33% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.